Baidu
map

J Thromb Haemost:华法林治疗稳定患者,实施延长INR检测间隔可行吗

2018-08-15 吴星 环球医学

既往单中心随机试验表明,国际标准化比率(INR)值稳定的患者可以延长检测周期至每12周接受1次INR检测。2018年7月,发表在《J Thromb Haemost》的一项研究考察了稳定华法林患者实施延长INR检测间隔的成功性。

既往单中心随机试验表明,国际标准化比率(INR)值稳定的患者可以延长检测周期至每12周接受1次INR检测。2018年7月,发表在《J Thromb Haemost》的一项研究考察了稳定华法林患者实施延长INR检测间隔的成功性。

目的:在一个基于实践的抗凝诊所多中心协作中,考察稳定华法林患者实施延长INR检测间隔的成功性。

方法:2014年至2016年,在6个抗凝诊所,基于既往INR值稳定性和华法林最小剂量的变化,确定符合延长INR检测的患者。研究者评价了抗凝诊所提供者对符合条件患者推荐的延长INR检测间隔(>5周)的频率。研究者也考察了患者的安全性结局,包括下一个INR值、出血事件和急诊就诊。

结果:在3362例使用华法林治疗的患者中,确定出890例(26.5%)患者至少有1个符合条件的延长INR检测时间段。总体而言,符合条件的患者对延长INR检测的使用率从2014年第一季度的41.8%增加至2016年第四季度的69.3%。使用延长INR检测与未使用延长INR检测的患者之间随后的超范围下一个INR值相似(分别为27.3% vs 28.4%)。两组之间的重大出血事件量没有差异,但使用延长INR检测间隔的患者的临床相关非重大出血率(0.02/100患者-年vs 0.09/100患者‐年)和急诊就诊(0.07/100患者-年vs 0.19/100患者-年)低于没有使用延长INR检测间隔的患者。

结论:稳定华法林患者使用延长INR检测可在不同基于实践的抗凝诊所成功和安全地实施。

原始出处:

Barnes GD, Kong X, Cole D, et.al. Extended International Normalized Ratio testing intervals for warfarin-treated patients. J Thromb Haemost. 2018 Jul;16(7):1307-1312. doi: 10.1111/jth.14150. Epub 2018 Jun 6.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008386, encodeId=38e820083866a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Apr 17 18:54:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803398, encodeId=6a9a1803398ba, content=<a href='/topic/show?id=3a91e530979' target=_blank style='color:#2F92EE;'>#稳定患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75309, encryptionId=3a91e530979, topicName=稳定患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 03 06:54:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933956, encodeId=57a21933956ac, content=<a href='/topic/show?id=0387988676' target=_blank style='color:#2F92EE;'>#INR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9886, encryptionId=0387988676, topicName=INR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Feb 01 21:54:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338751, encodeId=c416338e51f1, content=华法林凝血监测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 15 11:39:02 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2019-04-17 changfy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008386, encodeId=38e820083866a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Apr 17 18:54:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803398, encodeId=6a9a1803398ba, content=<a href='/topic/show?id=3a91e530979' target=_blank style='color:#2F92EE;'>#稳定患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75309, encryptionId=3a91e530979, topicName=稳定患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 03 06:54:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933956, encodeId=57a21933956ac, content=<a href='/topic/show?id=0387988676' target=_blank style='color:#2F92EE;'>#INR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9886, encryptionId=0387988676, topicName=INR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Feb 01 21:54:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338751, encodeId=c416338e51f1, content=华法林凝血监测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 15 11:39:02 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008386, encodeId=38e820083866a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Apr 17 18:54:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803398, encodeId=6a9a1803398ba, content=<a href='/topic/show?id=3a91e530979' target=_blank style='color:#2F92EE;'>#稳定患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75309, encryptionId=3a91e530979, topicName=稳定患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 03 06:54:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933956, encodeId=57a21933956ac, content=<a href='/topic/show?id=0387988676' target=_blank style='color:#2F92EE;'>#INR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9886, encryptionId=0387988676, topicName=INR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Feb 01 21:54:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338751, encodeId=c416338e51f1, content=华法林凝血监测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 15 11:39:02 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2019-02-01 zhaozuguo
  4. [GetPortalCommentsPageByObjectIdResponse(id=2008386, encodeId=38e820083866a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Apr 17 18:54:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803398, encodeId=6a9a1803398ba, content=<a href='/topic/show?id=3a91e530979' target=_blank style='color:#2F92EE;'>#稳定患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75309, encryptionId=3a91e530979, topicName=稳定患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 03 06:54:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933956, encodeId=57a21933956ac, content=<a href='/topic/show?id=0387988676' target=_blank style='color:#2F92EE;'>#INR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9886, encryptionId=0387988676, topicName=INR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Feb 01 21:54:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338751, encodeId=c416338e51f1, content=华法林凝血监测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 15 11:39:02 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2018-08-15 liumin1987

    华法林凝血监测。

    0

相关资讯

Stroke:无房颤的DVT/PE患者直接口服抗凝血剂与华法林的颅内出血风险

由此可见,DVT/PE患者就ICH风险而言,DOAC相比于华法林具有更高的安全性。

JAMA:美国预防工作组不建议用心电图筛查房颤:10秒“快照”没有比摸脉能发现更多房颤

JAMA杂志近日刊登了美国预防工作组(USPSTF)声明。声明指出,采用心电图在无症状人群中进行房颤筛查的获益及风险不明确,证据不足。

BMJ:直接口服抗凝药与华法林的风险和益处比较

总的来说,与华法林相比,阿哌沙班被认为是最安全的药物,其降低了大出血、颅内出血和胃肠道出血的风险。然而,与华法林相比,利伐沙班和低剂量阿哌沙班与全因死亡风险增加有关。

新的抗凝血药物可降低严重出血风险

近日,一项新的研究发现,用于治疗严重血栓的口服抗凝血剂(DOACs)与传统抗凝血药物华法林相比,可减少大出血的风险。该研究结果发表在BMJ上,为替代华法林的DOACs的安全性提供了证据。

Blood:高风险的抗磷脂抗体综合征患者不宜用利伐沙班替代华法林抗凝

中心点:目前,血栓患者抗凝治疗不考虑是否存在抗磷脂抗体。本试验显示,抗磷脂抗体综合征患者应用利伐沙班替代华法林抗凝,不良事件发生率增加。摘要:利伐沙班是替代华法林用于房颤和静脉血栓患者预防血栓形成的有效且安全的药物。利伐沙班是否同样可替代华法林用于血栓性抗磷脂抗体综合征高危患者尚不明确,Vittorio Pengo等人对此开展研究。研究人员进行一随机的、开放性的多中心非劣效性研究,招募狼疮抗凝血因

怕出血,停用华法林后又脑梗了……

病例的主人公是1位多次行房颤射频消融术的患者。出院后,主管医生电话随访时得知,患者因支气管扩张有点咯血,就停服华法林改用阿司匹林,不到1个月就发生了脑梗……

Baidu
map
Baidu
map
Baidu
map